We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

45 hedge funds and large institutions have $27.7M invested in TG Therapeutics in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 46 → 45 (-1)

18% less capital invested

Capital invested by funds: $33.6M → $27.7M (-$5.88M)

30% less call options, than puts

Call options by funds: $64K | Put options by funds: $91K

Holders
45
Holders Change
-1
Holders Change %
-2.17%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
14
Reduced
11
Closed
13
Calls
$64K
Puts
$91K
Net Calls
-$27K
Net Calls Change
-$27K

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$6.46M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$2.4M
3
SGAM
Smith Group Asset Management
Texas
+$794K
4
CCI
Columbus Circle Investors
+$654K
5
BM
Bridger Management
New York
+$594K

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$4.38M
2
RCM
RA Capital Management
Massachusetts
-$3.02M
3
Millennium Management
Millennium Management
New York
-$856K
4
SM
Sabby Management
Florida
-$846K
5
Neuberger Berman Group
Neuberger Berman Group
New York
-$636K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$46K +$47.5K +11,765 New
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$44K -$1.21K -300 -3%
CS
28
Credit Suisse
Switzerland
$42K +$44.5K +11,014 New
AIG
29
American International Group
New York
$40.2K +$7.07K +1,750 +20%
Citadel Advisors
30
Citadel Advisors
Florida
$30K +$31.4K +7,781 New
BA
31
BlackRock Advisors
Delaware
$29K +$1.48K +366 +5%
Group One Trading
32
Group One Trading
Illinois
$22K +$22.7K +5,631 New
SO
33
STRS Ohio
Ohio
$21K -$2.42K -600 -10%
Citigroup
34
Citigroup
New York
$20K +$18.7K +4,619 +738%
U
35
UBS
Switzerland
$8K -$1.39K -345 -14%
LTFS
36
Ladenburg Thalmann Financial Services
Florida
$6K +$6.26K +1,550 New
Morgan Stanley
37
Morgan Stanley
New York
$6K +$6.62K +1,639 New
TDC
38
Thompson Davis & Co
Virginia
$4K +$4.04K +1,000 New
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$2.98K +$3.09K +764 New
Bank of America
40
Bank of America
North Carolina
$2K -$29.9K -7,394 -93%
AllianceBernstein
41
AllianceBernstein
Tennessee
$2K -$9.7K -2,400 -83%
Barclays
42
Barclays
United Kingdom
$1K -$953 -236 -41%
Janus Henderson Group
43
Janus Henderson Group
United Kingdom
$1K – – –
RCM
44
RA Capital Management
Massachusetts
– -$3.02M -600,000 Closed
Millennium Management
45
Millennium Management
New York
– -$856K -169,749 Closed
Neuberger Berman Group
46
Neuberger Berman Group
New York
– -$636K -126,200 Closed
SM
47
Scoggin Management
New York
– -$445K -88,351 Closed
Fidelity Investments
48
Fidelity Investments
Massachusetts
– -$222K -43,600 Closed
WC
49
Wexford Capital
Florida
– -$151K -30,000 Closed
LOM
50
Loeb Offshore Management
New York
– -$82K -16,242 Closed
1
2
3

TGTX Hedge Fund Activity: Q4 2013 in Review

45 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2013, worth a combined $27.7M — down 18% from $33.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TGTX and 12 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $6.46M. The largest seller was Jennison Associates, cutting an estimated $4.38M.

  • 45 institutional investors held TG Therapeutics (TGTX) as of Q4 2013, down from 46 in Q3 2013.
  • Funds reported $27.7M of TG Therapeutics stock for Q4 2013, down 18% quarter-over-quarter.
  • 12 funds opened new TG Therapeutics positions in Q4 2013 and 13 closed out, a net change of -1 holder.
  • The largest TG Therapeutics buyer in Q4 2013 was Baker Bros. Advisors, an estimated $6.46M added.
  • The largest TG Therapeutics seller in Q4 2013 was Jennison Associates, an estimated $4.38M sold.

Based on aggregated 13F filings for Q4 2013.